Archives by Month
May 2008- 07: Patents Going Green
- 07: Patent Changes: Coming and Going
- 01: U.S. Patent Commissioner Speaks: Current Developments in Patents
- 01: Growth Opportunity: Interested in Becoming a Technical Specialist/Patent Agent?
- 30: Patent Office Receives Hate Mail Over Proposed Patent Changes
- 28: Are Patent Board Judge Appointments Unconstitutional?
- 26: World Intellectual Property Day 2008 – Celebrating Innovation
- 25: Are Biotech Companies Stymied In Dealing With Universities?
- 24: A Day in the Life of an IP Blog
- 23: Is the USPTO Striking Back With Double Patenting Rejections?
- 23: Written Description Materials, Revision 1
- 22: 505(b)(2) Drug Approvals Rock
- 21: Patents for Business
- 16: USPTO Rogers Pilot Program
- 14: Blogger Appreciation Day
- 11: Friday IP Round-Up
- 11: Court Pulls An “Or” Out Of Ortho-McNeil’s “And”
- 09: Generics Can Seek Declaratory Judgment Despite Covenant Not to Sue
- 07: Stupiderest Patent Reform Provisions
- 02: Coalition for Patent Fairness Thinks Patent Reform Is Near
- 01: No Joke, Court Smacks Down New Patent Rules
- 28: IPO Urges Action Against Patent Reform Bill Provision
- 27: IP Associate Position Available
- 21: Friday IP Round-Up
- 21: AGs Feel Chest Pains Over Generic TriCor
- 21: Senior Licensing Associate Opening
- 20: Abbott’s HER2 Patent Narrowed
- 20: Pfizer Feels Pain Over Celebrex
- 17: PharmaBiotech IP 2008
- 14: Friday IP Roundup: Pi Edition
- 12: Troll Tracker Sued For Defamation By Lawyers
- 11: Patent Office: Application Costs Could Increase by $100,000 or More
- 07: FDA: Don’t Do As We Say or You’re Out of Luck
- 06: Bilski: Much Ado About (almost) Nothing
- 05: Patent Office Will Now Require Biological Deposits Before Publication
- 04: (Anti-)Trust Me, You’ll Love This Blawg Review
- 04: The Butterfly Effect of FDA Regulations
- 03: Ding! WARF Wins Round 2 As Stem Cell Patent Upheld
- 29: Patent Office Director: Patent Allowances Down, Hoorah!
- 29: Friday IP Round-Up
- 19: Can Approval of Biogenerics Really Save Money?
- 15: Friday IP Round-Up
- 15: Brazilian Government Published Bill on Bioprospecting/Biopiracy
- 14: Don’t Play Mind Games With Trade Secrets
- 14: Ohio Valley Affiliates for Life Sciences (OVALS) Regional Conference in Louisville, KY
- 13: Farmer David Reaps What He Has Sown: A Patent Suit
- 08: Patent Rule Injunction, Court To Sleep On It
- 06: Bayh-Dole Act Does Not A Patent Law Make (The Dissent)
- 06: The Patent Blog List
- 05: The Super Bowl of Blawg Reviews
- 05: Bush Administration Calls For “Tech Neutral” Patent Reform
- 05: Examination Support Document (ESD) Could Add $26,000 to Patent Costs
- 04: Bush Administration To Patent Office: Hey, Hold Up There Mister On That There Reasonable Royalty Rate
- 31: Will You Be Allowed To Use Those Patented Parts You Purchased Any Way You Like? Not Unless You’re Exhausted
- 30: Want To Make Your Documents Available To Others?
- 30: Reducing the Cost of European Patents: The London Agreement
- 28: Terms of Use
- 26: Bayer Learns That Note-Taking Can Come Back to Bite Your Patent
- 25: USPTO to Administer National Medal of Technology and Innovation
- 22: Can States Have Their (Patent) Cake and Eat It, Too?
- 18: Abbott Learns Not To Turn In Its Homework At 9:30 p.m. On The Night Before The Test
- 18: The Patent Office Has Become A National Disgrace (circa 1930)
- 17: Patent Reform: What Does First-To-File Mean To Me?
- 17: Senate Committee Gives Thumbs Up To Patent Reform Bill
- 14: Oops, They Did It Again — Patent Office has “Typographical Error”
- 11: Brief Highlights Patent Office’s “Suspicious Procedures”
- 08: Sides Line Up in Impending Patent Continuations Fight
- 19: Changes to the European Patent Convention
- 19: London Calling: What the London Agreement Means to You
- 12: Raymond Niro Responds to Patent Troll Tracker
- 11: Bill Introduced to Allow FDA to Remove OTC Drugs From the Market
- 11: Thinking About IP
- 11: Reviewing Blawgs, de novo
- 10: When is a Patent Office Appointee Qualified? Judge Says Always.
- 10: Bounty On The Blawger?
- 07: Tango With Ideas
- 06: Apotex Loses Patented Process Merck Was Already Using After Court Agrees It Wasn’t Concealed
- 04: CAFC: Extrinsic Evidence Can Only Be Used Against You
- 03: Barista Suit Proceeds Against Starbucks Cluster-Bombing
- 28: Patent Baristas Picked As One Of The ABA Journal’s Blawg 100
- 28: Federal Circuit: States Have Their Cake and Eat It, Too (At Least With Patent Lawsuits)
- 26: A Patent License Does Not Create A Suit Under Patent Laws
- 20: Patents Are Now A Wiz
- 19: Patent Office: “Hey, Where’s Everyone Going?”
- 12: Tricks With Patents
- 12: Marathon Blawg review
- 08: Patent Barista Mugs At BioOhio (And One Free Registration Offer!)
- 08: Corn Growers Like Patent Reform; Venture Capitalists Not So Much
- 08: Comments In For Proposed Rule Changes to Patent Appeals
- 07: Calling for Dialogue on Intellectual Property Rights
- 07: Michigan Law Review Symposium on Patent Law
- 01: Is the Public Interest Really Upheld by the New USPTO Rules?
- 31: Patent Reform Act of 2007: Responding to Legitimate Needs or Special Interests?
- 31: Duality: Light and Dark Forces Line Up For and Against Patent Reform
- 31: Court Blocks New USPTO Rules on Continuations and Claims — For Now
- 26: Time Running Out to Block New Patent Rules
- 24: Groups Challenge USPTO Rule Changes Based on Outrageous Cost to the Public. Will the OMB Care?
- 16: Clustering Your IP Results
- 16: Blawg Review: The Dual Hemisphere Edition
- 14: Apotex Gets Out of Contempt Holding — But Only Because Injunction Didn’t Mention ANDAs
- 12: Patent Wars Episode II: GSK Strikes Back
- 11: Can There Always Be A Rationale That An Invention Is Obvious?
- 11: Guidelines for What’s Obvious
- 11: Do the New Rules Exceed USPTO Rulemaking Authority? (pt. 3)
- 09: Do the New Rules Exceed USPTO Rulemaking Authority? (pt. 2)
- 08: Do the New Rules Exceed USPTO Rulemaking Authority? (pt. 1)
- 08: Simply the Best Blawg Meme
- 05: FDA Wants to Put Generic Drug Approval in Faster Lane
- 01: Should Peer-To-Patent Review Be Made Compulsory?
- 01: Get Your Own (IP) Watchdog
- 29: Cleveland Clinic 2007 Innovation Summit
- 28: Who’s Minding the FDA?
- 28: FDA Wants Your Comments on 180-Day Exclusivity Forfeiture
- 28: FDA Act Brings Big Changes
- 27: The Search for Personalized Medicine
- 26: Biotech Business Trends Looking Good
- 26: Patent Claims Must be Read in View of the Specification
- 21: Let’s Make a Deal: Is Your Company An Acquisition Candidate?
- 18: CEO of BIO Holds Discussion with Biotech & Pharma bloggers
- 17: Will Follow-On Biologics Bill Become Law?
- 17: Pharma Find Patents More Elusive for Stereoisomers
- 10: House Passes Amended Version of Patent Reform Act of 2007
- 06: Can You Get an Injunction Against A Possible Contributory Infringer?
- 06: Innovation v. Monopoly - The “NO” Video
- 05: House of Representatives to Consider Patent Reform Act
- 05: POPA Joins the Crowd in Opposing Patent Reform Act
- 05: Patent Baristas Ranked Best In Intellectual Property (Again!)
- 31: CAMBIA Extends Patent Resource to Include Australian Patents
- 24: Is the Tide of Willful Patent Infringement Litigation Receding?
- 23: Inventor Challenges Patent Office Rules in Virginia
- 23: Blawger Bowl IV Gearing Up; Expansion Teams Available
- 22: Patent Office Takes Applicants to the Woodshed For Sending Too Much Work
- 20: USPTO to Publish New Claim and Continuation Rules: Will They Improve Efficiency of Patent Examination?
- 14: Want to Volunteer with the Patent Office?
- 14: USPTO to Limit Markush (Alternative) Claims: Serious Cost Increase in the Forecast
- 13: Inspired Blawg Review
- 11: Bad PR Move?
- 08: CincyTech Looking for a Bioscience Executive-in-Residence
- 08: The Dog Ate My Homework Butt-Saving Bill to be Slipped into the Patent Reform Act
- 04: Contributors
- 03: Is the Use of a Patented Formulation or Delivery Technology Safe under the FDA Research Exemption “Safe Harbor”?
- 03: You Just Can’t Make the USPTO Director Do Something (Unless It’s in the Statutes)
- 02: Status of Research Tool Patents Still in Limbo
- 01: Monsanto Planted By Patent Office Re-Exam
- 01: Top 10 Best Blogs In Cincinnati
- 30: Another USPTO Rule Package Slowly Boxing In Applicants
- 30: BlawgWorld 2007 with TechnoLawyer Problem/Solution Guide: Available Now
- 27: The Myths of Doha: Compulsory Licenses
- 26: How Can You Tell If A Patent Has Truly Expired?
- 25: AstraZeneca Loses Over Double-Patenting of Toprol-XL® Ingredient
- 25: Gilead Sciences Pwned by Nonprofit Activists
- 23: Has the Plaintiff Chooses the Forum Rule Been Eliminated For Patent Holders?
- 19: Patent Reform Bill Inches Ahead (As Amended)
- 11: Patent Baristas Picked as a Top 5 Biotech Blog
- 11: No Patent Infringement if Any Steps of a Method Can be a “Service”
- 10: Can You Sue to Remove a Political Appointee That Doesn’t Meet the Job Description?
- 10: OMB Approves Patent Changes, But to What Result?
- 09: Federal Circuit Drives Another Nail into DOE Coffin
- 06: Patent Holders Express Budget Concerns Over Proposed Patent Rule Changes
- 05: Patent Baristas: Burned By Feedburner Feed
- 05: DOJ: US Needs More Prior User Rights
- 03: For Chemical Obviousness, Need to Show That Prior Art Suggested Making Modifications to Get Claimed Compound
- 28: Senate Committee Approves Follow-On Biologics Bill: Fear and Trepidation Follow
- 27: USPTO: “If you want all your claims examined up front, you can have it done, but it’s going to cost you”
- 27: Supreme Court Takes a Bye on Reverse Payments — Again
- 26: Draft Bill Lays Down Path to Follow-On Biologics
- 20: Patent Reform Letter: The Re-Mix
- 20: Means Plus Function Without Describing the Means is No Means for a Patent
- 20: Patent Blog Gone Wild
- 19: Apotex Dies Harder on Plavix Bid
- 18: Chief Justice Michel Writes to Committee on Patent Reform
- 12: Judge Michel Writes Letter on Damages in Patent Infringement Cases
- 12: Senate Judiciary Republican Letter on Patent Reform
- 08: Bristol-Myers Squibb Pleads Out On Plavix Deal
- 07: Supreme Court Urged to Take Up Case on Government Taking of Patent Rights
- 07: Do Authorized Generic Drugs Deter Paragraph IV Certifications?
- 06: Brazil Signs Compulsory License for Efavirenz
- 04: Re-Planting Biotech Crops A No-No
- 25: Solicitor General Says Tamoxifen Case Not a “Good Vehicle”
- 24: Chief Justice Michel Weighs In On Patent Reform
- 23: Drug Basics Workshop: Discovery, Development & Testing
- 22: Federal Circuit Snubs Pfizer On Norvasc Rehearing
- 21: IP Items From The Web
- 18: Department of Commerce Gives Its Two Cents on Patent Reform
- 16: Companies Send Concerns to Congress on Patent Reform
- 15: Supreme Court Won’t Hear Review of Claim Construction
- 10: Security Tight At BIO2007
- 09: Protesters Fear Unintended Consequences
- 07: BIO2007 Exhibits in Full Swing
- 05: Microsoft Exploits Loophole in Patent Law. And what you can learn from this!
- 04: BioVoice: Blogging from BIO 2007
- 03: Who Should Bear the Burden of a Heathcare Crisis?
- 02: Could KSR Ruling Hurt Biotech and Pharma Companies?
- 01: It’s Obvious That Everyone’s Talking KSR
- 30: Supreme Court Makes Holding Patents More Difficult
- 27: Patents Are For Chumps
- 26: Celebrate World Intellectual Property Day
- 25: VC Money Pours Into Biotech; But Not the Midwest
- 24: Recognizing a Novel Characteristic After the Fact Doesn’t Make a Known Composition New Again
- 23: For Now, Mylan Remains Sole Generic Norvasc Seller
- 22: Zoltek Corp. v. U.S.: Protecting Patent Holders from Government Infringement
- 16: Breakfast in Boston
- 12: A Little About Patent Baristas
- 12: Abbott Tries New Approach to Kaletra/Aluvia Pricing
- 12: Of BRICs and Mortar: Technological Drivers in Booming Economies
- 06: Abbott Ups the Ante in Thailand Patent-Breaking
- 05: More Legal Research Tools
- 03: WARF Stem Cell Patents Knocked Down in Round One
- 02: IP Blog Monday
- 30: Patent Term Extension is OK, Even With a Terminal Disclaimer
- 30: Court Pooh-Poohs Novartis’ One-Patent-at-a-Time Lawsuit Tactic
- 30: New FedCirc.us Caselaw Search Tool
- 27: Supreme Court to Solicitor General: What Say You On Reverse Payments?
- 27: FDA to Biotech Investors: Relax, You Have Years Before Competition Ramps Up
- 26: FDA Chief: Biogenerics will be Similar, Not Interchangeable
- 22: Patents Found Invalid Against One Party Are Unenforceable Against Another Party
- 22: Why A Pediatric Exclusivity Add-On?
- 22: Pfizer’s Norvasc Patent Finally Goes Down After Taking Plenty of Punches
- 19: Proof That the U.S. Patent and Trademark Office Hates Me
- 09: Five Things You Didn’t Know About Me
- 09: Harvard Drug Slaps Purdue Pharma with Antitrust Suit over OxyContin
- 08: Tercica and Genentech Settle Infringement Suit Against Insmed
- 07: Senate To Hear About Biogenerics
- 06: Trade a Patent, Get an iPod
- 27: Generic Drug Companies Ruffled by Increases in FDA User Fees
- 21: USPTO Smacks Down Genentech’s Antibody Patent
- 21: Novozymes Gets Double the Fun after Danisco Found to Have Willfully Infringed
- 16: Bill Re-Introduced to Create Path for Biogenerics
- 15: House Creates Specialized Patent Trial Judges
- 14: Happy Valentines Day
- 13: Representatives Introduce Bill to Stop Gene Patents
- 12: Sanofi Patent Found Unenforceable Due to Inequitable Conduct
- 31: New Magazine to Cover Federal Circuit Patent Decisions
- 30: CAFC: The Recapture Rule is Separate from Construction
- 29: Not Claiming a Range Can Make “About” Something More Precise
- 29: Participating in an Interference Waives State’s Immunity
- 24: Is it Worth it for Generics to Challenge Branded Drugs?
- 24: More On Ariad v. Lilly re Evista, Xigris
- 18: Trouble With Tech Transfer…Or Expectations?
- 17: FTC Sees Increase in Reverse Payment Settlements
- 17: Practical Implications of MedImmune
- 16: Senate Committee Hears Arguments Regarding Reverse Payments
- 16: Court Upholds Andrx Preliminary Injunction For Generic Biaxin
- 10: Learn How to Make Money From Your Company’s IP
- 10: Supreme Court High-Fives MedImmune
- 05: Reliant Pharma Sues Par Over ANDA Filing
- 05: Patent Law is a Circus
- 05: Infringement Verdict Upheld Against Abbott
- 04: It’s a New Year So There Must Be Calls For Patent Reform
- 03: Sip & Spit Not Disavowed in Ventana’s Patent Suit
- 02: CAFC: You Still Need Motivation to Render Drug Patent Obvious
- 24: Is Congress Set to Give the World an IP Gift?
- 21: Could the FDA Put the Squeeze on Off-Label Revenues?
- 21: New Law To Dole Out $1 Billion to Biotechs for Vaccines
- 18: HealthBlawg Tickles the Keys
- 15: Public ’s Interest In Better Treatments Prevents Preliminary Injunction
- 15: Google Offers Yet Another Beta: Google Patent Search
- 14: Corporate Patent Congress 2007
- 13: Thailand Issues Compulsory License to AIDS Drug
- 13: FDA Panel Gives Mixed Review on Coated Stents
- 12: Therapy Over Coffee
- 12: Archives by Category
- 12: Archives by Month
- 11: Apotex Smacked Down on Plavix
- 07: Purgatorio, from Infamy or Praise
- 06: Is the Government Keeping More Inventions Secret?
- 05: Votes Are In (Sort Of)
- 05: NIH Scientist Could Get Prison and $100K Fine
- 04: Can the Abandoned Parent of a CIP be Revived as Unintentional?
- 04: About Your Baristas
- 29: CAFC: Enablement for 102 Not the Same as Enablement Under 112
- 28: Supreme Court Hears Arguments in KSR
- 28: Amgen V: Does It Matter How Therapeutically Effective Amount is Construed?
- 27: Due Diligence Monday: Basic IP Due Diligence
- 21: Court: When is a Pentetate Equivalent to an Edetate?
- 17: D.C. Circuit: Merck Can’t Pull the Rug Out From Under Para IV Listers
- 16: The Importance of Being Earnest (and Getting Things in Writing)
- 15: Biotech Drugs: How to Spend $1.2 Billion
- 14: Upcoming Conference on Biotech Patents
- 13: Daily Dose of IP
- 10: New Found Property Doesn’t Make Known Material Novel
- 04: Poll: Your Top Legal Blog
- 03: Friday Editorial: What Do the Elections Mean to Pharma?
- 03: Relieving the Duty to Pay Royalties– Go Medical v. Inmed Corp.
- 03: Is Dr. Reddy’s Playing It Smart? Or Is It Glaxo?
- 02: Invitrogen Gets Triple Damages in E. coli Competent Cell Case
- 31: Eisai Prevails: Motion For Summary Judgement
- 30: Due Diligence Monday: Copyrights
- 30: Imitrex - Authorized Generic Steps In
- 27: Mylan Wins One, Loses One
- 25: Ariad v. Lilly Part Duex: IP Suit Marches On
- 23: Read and Become a Billionaire in Four Easy Steps
- 20: Should Doctors Be Paid To Give Inside Info To Wall Street?
- 19: Are Conflicts of Interest on The Rise?
- 19: Statins – The Game Begins
- 11: Supreme Court Leaves Apotex Hanging with Zoloft Patent
- 06: Friday Biotech Wrap-Up
- 05: MedImmune Asks: What’s A Patent Lawsuit Among Friends?
- 04: WARF Backhanded by PUBPAT
- 02: Blawg Review #77
- 29: Autumnal Edition of Blawg Review: Call For Submissions
- 28: The Market Price for Biotech Drugs
- 25: Due Diligence Monday: Patents
- 22: The Road To BioGenerics
- 21: Publish and Perish
- 20: ImClone Loses Patent Due to Lack of Written Records (and Unclean Hands)
- 18: AstraZeneca Asks to List Delivery Device in Orange Book
- 15: Friday IP Wrap-Up
- 14: KSR International v. Teleflex
- 14: Upcoming BIO Mid-America VentureForum
- 13: Expert Testimony Can Provide Motivation to Combine References
- 12: Innogenetics Wins $7 Million in HCV Patent Suit Against Abbott Labs
- 11: The Gloves Are Off (And The Governors Are A-Calling)
- 08: Apotex Files Appeal of the Plavix Injunction
- 08: Wiki Patent Palooza
- 07: NF-κβ Patent Reexamination Update
- 07: Genentech v. MedImmune Briefing
- 07: IP Law Daily
- 06: Court Rules Compounding by Pharmacists is Legal
- 06: IP Blawgs of Note
- 05: Baristas to Compete in Blawger Bowl III
- 05: Apotex Injunction Doesn’t Mention eBay Standards for Preliminary Injunctions
- 01: USPTO Five-Year Plan Threat Level: Severe
- 31: Court Blocks Generic Plavix by Apotex
- 31: Novozymes To Win Some Green on Green Technology Patents
- 29: Endo and Purdue Pharma Settle Suit Over OxyContin Patents
- 29: We’re Looking for a Patent Litigation Associate
- 25: GPhA Says PhRMA Study on Authorized Generics Lacking
- 24: If You Want to be Named a Co-Inventor on a Patent, Don’t Swear You’re Not
- 22: Patent Reform Act - Senate Version
- 21: Eggs Over Easy
- 18: FDA Deflates Canned Air
- 17: ZymoGenetics Goes After Bristol-Myers for Infringing Fusion Protein Patents
- 16: Amgen IV: The Return of the Therapeutically Effective Amount
- 15: Update: Sanofi and Bristol-Myers File for Preliminary Injunction Against Apotex
- 11: Federal Circuit Affirms University’s 11th Amendment Immunity
- 09: FDA Forms Nanotech Task Force
- 09: Apotex To Launch Generic Plavix At Its Own Risk
- 08: The Federal Circuit Explains Why Inventors Need Support That Experiments Were Actually Performed
- 04: Matchpoint: Pfizer Loses on Form Over Substance
- 02: Wyeth Sued Over Patent On Controlled Release Version of Antidepressants
- 29: Nanotech Lust Hits VCs With Promise of $1 Trillion Payday
- 27: Jury Finds Stratagene Infringed On Invitrogen’s Patent for Making Competent E. coli
- 27: More Questions Arise Concerning Drug Approval Process
- 26: Trial Counsel as Opinion Counsel
- 25: FreePatentAuction Is Just That, Free
- 24: From Sending the Internet to Bulked Up Golfers
- 24: Bill Introduced to Limit Authorized Generics
- 21: Are There Competitive Problems in Pharmaceutical Markets? The FTC says “Yes”
- 20: The Future of Patent Policy In Europe? Dissent.
- 19: What a Diff’rence a Day Makes!
- 18: Pushing Buttons
- 12: MedImmune v. Genentech
- 12: USPTO Director Named in Suit By Enzo Therapeutics Over a Denied Petition to Revive
- 11: Patent Baristas Ranked Best In Intellectual Property
- 11: USPTO Requesting To Do Less In Examining Patents
- 10: Nektar and University of Alabama Settle PEGylation Litigation
- 07: Will the ‘Preserve Access to Affordable Generics Act’ Really Preserve Access to Affordable Generics?
- 06: FTC Rejects Patent Deal by Bristol-Myers and Sanofi
- 06: Teva Launches, then De-launches, Generic Biaxin® (Clarithromycin) XL
- 29: Pfizer Plans to Introduce Generic Zoloft - Will Teva have Another Bad Day?
- 29: Vaya con Dios, LabCorp v. Metabolite
- 28: One More Try: UK court rejects Ranbaxy’s appeal on Lipitor patent
- 27: Fed Circuit Vacates Preliminary Injunction on Generic Biaxin XL
- 27: The Generic 23/6: The Day Belongs To?
- 26: Hurts So Good: US Supreme Court Refuses to Hear Patent Antitrust Case
- 23: New Article Comparing PTO ethics with State Rules
- 23: Patent Agents, Patent Lawyers, Nonlawyers…
- 22: Karma Chameleon
- 21: The Federal Circuit & Section 271(f)(1)
- 20: Another One Bites the Dust - Merck’s Zocor Loses U.S. Patent Protection Friday
- 19: Next Generation Treatments for Alzheimer’s – Prevention and the Diabetes-Alzheimer’s Link
- 14: A New Specialty Blend
- 13: Baristas in Boston
- 12: Barr Labs and Novartis Settle Warfarin Litigation
- 12: FDA Enacts Measures to Stop Counterfeit Drugs
- 10: Sanofi Suspends Tests on Antibiotic Ketek
- 05: Recombinant Antithrombin Recommended for Approval by European Committee
- 03: USPTO Biotech Backlog: Bad, Getting Worse, No End in Sight
- 02: No Requirement for Recitation of a Known Structure in a Biotech Case
- 02: 2006 TechnoLawyer @ Awards: Blawggers of the Year
- 01: Associate Position Available in Biomed/Pharma
- 31: Is the FDA Set To Bring On Generic Biologics?
- 30: WHO Releases Report Promoting Innovation Relevant to Developing Countries
- 26: The Biggest Thing in Nano Isn’t Coming from Apple
- 25: Herceptin Approved By EC for Early-Stage HER2-Positive Breast Cancer
- 22: Vaccine for Cervical Cancer Closing in on FDA Approval
- 22: Will WHO’s Call for Clinical Trial Registration Help or Harm the Public?
- 22: Tech Law Advisor Provides Wall-to-Wall Blawg Coverage
- 21: BlawgWorld 2006: Capital of Big Ideas
- 19: Acambis Fights Patent Suit over Smallpox Contract
- 19: Patent Lens Provides Patent Informatics Tools
- 18: Amgen Challenges Validity of Ariad NF-kB Patent
- 18: The Real Code is Finally Published
- 16: It Only Takes One Determined Individual to Bring Down a Patent
- 15: Supreme Court Shifts the Balance of Power In Patent Infringement Cases
- 12: Biotech Booming, 30 Years On
- 09: EU Court Holds that an Ingredient that Controls the Release of an Active Ingredient Doesn’t Make a Combination
- 08: Point of Law Sweeps Week
- 05: Federal Circuit Sets Out Personal Jurisdiction Standard
- 04: Can a Known Drug Infringe a Later Issued Patent on the Pathway of Action? A Jury Says Yes.
- 03: Ranbaxy & Teva — the Last Laugh
- 27: Eli Lilly Ordered to Hand Over Patent Application to Collaborator
- 26: Generic Companies Paid to Drop Patent Challenges
- 24: Terminally Disclaimed Patents Not Barred from Obtaining a §156 Extension
- 19: European Commission Approves First Biogeneric
- 18: The Price of Pharmaceuticals
- 18: A District Court Judge Orders FDA to Rule on Biogenerics
- 17: Law, Taxes and Cars
- 17: Bill Introduced to Allow Unintentional Delay in Filing for Drug Patent Term Extensions
- 14: Do Drug Companies ‘Gouge’ Consumers With Taxpayer Handouts?
- 13: CAFC: Failure to Disclose Information May Have Been Inadvertence
- 12: State Dollars Flow at BIO 2006
- 10: Carnival of Biotechnology
- 06: The Patents Depend on Quality Act of 2006
- 05: Midwest Will Be Next Biotech Hotbed
- 04: Pin All Your Romantic Hopes on Google
- 03: A Fool and His Blawg Review
- 01: Google Inc. to Acquire Patent Baristas for $1.3 Billion
- 31: FTC Eyes Impact of Authorized Generic Drugs
- 30: USPTO Proposes Rule Changes for Reexamination
- 30: Supreme Court Hears Arguments for & Against Injunctive Relief in Infringement Cases
- 29: Baristas to Host Next Carnival of Biotechnology
- 28: Medtronic Sues Guidant in Ireland on Coated Stents
- 24: Does Sanofi-Aventis Patent Settlement With Apotex Reveal a Trend?
- 24: CAFC: A Salt Doesn’t Literally Infringe an Acid Claim
- 23: DC Circuit: Courts Not to Choose Between Competing Meanings of an Ambiguous Statute Without Agency Interpretation
- 22: Are Patents a Form of Blackmail?
- 20: Cordis Wins Suit on Stent License
- 20: TechnoReview: The SmartDraw Legal Solution
- 17: USPTO Launches Web-Based Filing System for Patent Applications
- 16: FDA Outlines Critical Path Opportunities List
- 15: European Medicines Agency Sets Guidelines on Biosimilar Drugs
- 13: Rethink(ip) Blogs with Unfettered Discretion
- 10: Anti-Stacking Provisions Can Help Minimize Total Royalty Burden
- 07: Three-Year Market Exclusivity Extension for a New Indication of a Drug
- 03: Blawgr Set to Be Collaborative Law Blog
- 01: WSJ: Rise in Patents Due to Innovative Lawyers, Not Genuine Innovation
- 28: A Known Product Anticipates the Product by a Novel Process Claim
- 28: Submarine Patent That Surfaced After 24 Years Costs Monsanto $100 million
- 27: GlaxoSmithKline Gets Restraining Order Against Generic Flonase
- 24: EU Turns Down Drug Made In Goats’ Milk
- 23: Toprol-XL: A Pyrrhic victory for Generic Manufactures
- 22: Supreme Court to Review MedImmune’s Bid to End License Payments on Synagis
- 16: Patent Found Unenforceable Due to Inequitable Conduct With Submitted Declarations
- 14: European Medicines Agency Recommends Approval of Omnitrope as a Generic Biologic
- 10: Demystifying HR2795: The Patent Act of 2005 (Part 10)
- 09: Former Professor Sued For Patent Infringement
- 09: Demystifying HR2795: The Patent Act of 2005 (Part 9)
- 08: Demystifying HR2795: The Patent Act of 2005 (Part 8)
- 07: CAFC Underscores Need to Corroborate Reduction to Practice
- 07: Demystifying HR2795: The Patent Act of 2005 (Part 7)
- 06: Reasonable Diligence Can be Shown by Laboratory Notebooks
- 06: Demystifying HR2795: The Patent Act of 2005 (Part 6)
- 03: Demystifying HR2795: The Patent Act of 2005 (Part 5)
- 02: Demystifying HR2795: The Patent Act of 2005 (Part 4)
- 01: CAFC Hands Purdue Pharma a Reversal of Fortune in OxyContin Case
- 01: Demystifying HR2795: The Patent Act of 2005 (Part 3)
- 31: Demystifying HR2795: The Patent Act of 2005 (Part 2)
- 30: Demystifying HR2795: The Patent Act of 2005 (Part 1)
- 30: Cyberlaw Central Brings the Hitchhiker’s Guide to the Blawgosphere
- 27: Collateral Estoppel Doesn’t Apply to Design-Around Efforts
- 25: Documenting Inventions
- 25: Unwitnessed Notebooks Alone Insufficient To Support Co-Inventorship
- 23: Carnival of the Capitalists #120
- 19: Status of Pfizer’s Viagra Patent Re-Exam (Update 2)
- 18: Drug Patent Deals Raise FTC Concerns
- 18: Mid-Level Patent Associate Opening
- 13: FDA Issues New Guidelines to Help Small Drug Companies in Early Stage Development
- 11: A Silver Lining in the Expiration of the PCR Patents
- 09: Bruce MacEwen Has An Epiphany
- 05: Patent Infringement Updates
- 04: A European Viewpoint on USPTO Patent Pendency
- 04: Is There A Patent Epidemic?
- 03: USPTO Proposes Limiting Continuations
- 03: The Unbalanced Equation of Profs. Lemley, Lichtman, Sampat
- 02: The Secrets of Legal Underground, Revealed
- 30: Federal Circuit Finds Distinction Between Topical Application For Treating v. Avoiding Sunburn
- 29: Genentech Puts Science Over Commercial
- 28: Patent Baristas Listed as a Top 10 IP Source Site
- 26: Ranbaxy and Cephalon Settle Patent Tiff Over Provigil
- 26: Baristas Win Best Blawg Theme
- 25: Adeste, Fideles
- 24: Peace On Earth
- 21: Andrx Files Patent Infringement Suit Against GlaxoSmithKline Over Wellbutrin XL
- 20: Should Drugmakers Be Made Bulletproof?
- 19: What Price Therapeutics?
- 16: District Court Hands Pfizer a Win in Lipitor Case
- 16: Muckraking Columnist Takes on Biotech Industry
- 14: A Biotech Patent Bubble?
- 13: India Fights Back Against Biopiracy
- 07: WTO Amends Rules on Generic Drugs
- 07: Status of Pfizer’s Viagra Patent Re-Exam (Update)
- 06: Nine Circles of Hell in Infamy or Praise
- 05: Cambridge Faculty Divided Over Proposed Changes in IP Ownership
- 04: Jones Day Lawyers Join Frost Brown Todd
- 03: New Zealander Takes on Amazon’s Patent
- 02: PUBPAT Claims “Substantial” Victory in Lipitor Patent Challenge
- 01: CAFC Upholds Preliminary Injunction Against Ranbaxy and Teva